Skip to main
GILD

Gilead Sciences (GILD) Stock Forecast & Price Target

Gilead Sciences (GILD) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 50%
Buy 38%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Gilead Sciences is a global commercial-stage biotechnology company that specializes in virology and infectious disease, although it’sbecoming a bigger player in the oncology space and has built out a deep pipeline across oncology and virology. The recent FDA acceptance of 300 mg QW oral Yeztugo (NDA expected by Feb 2027), along with stronger-than-expected uptake of Yeztugo among PrEP-naive patients, bodes well for continued growth in this franchise and sets up for Gilead to offer multiple dosing options under a single brand, enhancing its commercial narrative and market position. Gilead also holds potential for meaningful near-term growth from its CAR-T cell therapy anito-cel, with initial revenues expected in 1Q27 and potential for expansion into earlier lines of therapy. Overall, Gilead's solid performance across key products, coupled with its commitment to sustainability and transparency, make it a strong investment opportunity.

Bears say

Gilead Sciences is one of the leaders in the biotech industry, with a strong track record of successfully navigating through patent cliffs. Their current portfolio includes blockbuster drugs in the HIV and hepatitis B and C markets, with potential for growth in the oncology field through strategic acquisitions and partnerships. While concerns about PrEP persistence have caused the stock to underperform in the short term, the company's strong financials and pipeline optionality make it a compelling long-term investment opportunity.

Gilead Sciences (GILD) has been analyzed by 16 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 38% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Gilead Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Gilead Sciences (GILD) Forecast

Analysts have given Gilead Sciences (GILD) a Buy based on their latest research and market trends.

According to 16 analysts, Gilead Sciences (GILD) has a Buy consensus rating as of Jul 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $155.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $155.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Gilead Sciences (GILD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.